Breast Cancer, Cancer
Conditions
Brief summary
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
Interventions
BEHAVIORALConditioning Resistance Training
Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training".
BEHAVIORALStrength Resistance Training
Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8".
BEHAVIORALHypertrophy Resistance Training
Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm".
Sponsors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
1. Age 20-89 years 2. Women prescribed exercise as a SOC 3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast 4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed. 5. Women with \> 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center
Exclusion criteria
1. Any current treatment with cytotoxic chemotherapy for breast cancer 2. Inability to safely engage in group sessions of resistance training as deemed by study PI 3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training 4. Pregnant women 5. Males
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Myokine Production After First Exercise Session | Immediately before and immediately after the first exercise session. | Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined. |
| Change in Myokine Production After Final Exercise Session of Each Week | Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4. | Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined. |
| Change in Myokine Production After Final Exercise Session of the Month (End of Study) | Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen). | Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined. |
Countries
United States
Contacts
CONTACTClinical Trials Contact
PRINCIPAL_INVESTIGATORColin Champ, MD
AHN Radiation Oncology
Outcome results
None listed